Qu Biologics’ Immunomodulator Improves Fatty Liver Disease
06 janv. 2025 08h00 HE
|
Qu Biologics, Inc.
BURNABY, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunomodulation...
Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor
16 déc. 2024 08h00 HE
|
Qu Biologics, Inc.
BURNABY, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
GEn1E Lifesciences appoints François Nader, MD as Chair of its Board of Directors
11 déc. 2024 07h01 HE
|
GEn1E Lifesciences Inc.
Dr. Nader, current Independent Board Director at Moderna and Senior Advisor at Blackstone Life Sciences, joins GEn1E Lifesciences board as chair.
Immunomodulators Global Business Analysis Report 2024-2030: Growing Focus on Combination Therapies Enhances Market Opportunities, Increased Focus on Developing Targeted Therapies
07 nov. 2024 10h43 HE
|
Research and Markets
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Immunomodulators - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Immunomodulators...
GEn1E Lifesciences Publishes Breakthrough Research Unveiling Novel Mechanism of Action of Dual Signal Modulators for Anti-inflammatory and Endothelial-Stabilizing Therapies
14 oct. 2024 06h02 HE
|
GEn1E Lifesciences Inc.
GEn1E Lifesciences today announced the publication of a landmark study in the prestigious Journal of Pharmacology and Experimental Therapeutics (JPET)
Global Immunomodulator Market Projected to Nearly Double, Reaching $477.55 Billion by 2034 - Evolution of Immunomodulatory Treatments for Cancer Creating Lucrative Opportunities for Oncology Applications
27 juin 2024 09h43 HE
|
Research and Markets
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Global Immunomodulator Market" report has been added to ResearchAndMarkets.com's offering.In a significant development for the healthcare industry,...
Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly
07 juin 2024 20h18 HE
|
Qu Biologics, Inc.
Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial...
Herbal TB Immunotherapy to be Presented at Hong Kong Conference
07 juil. 2011 10h33 HE
|
Immune Network Ltd
VANCOUVER, British Columbia, July 7, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF) advises that clinical results from its new tableted form of Immunoxel (Dzherelo) product...
Immunitor Publishes Interim Data From Phase IIb imm01 TB Trial
30 déc. 2010 04h41 HE
|
Immune Network Ltd
VANCOUVER, British Columbia, Dec. 30, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), advises that Immunitor has published data from the first half of the 120-patient imm01 clinical...
Immunitor Phase 2b imm01 Trial Enrollment Scheduled to Complete Next Week
01 nov. 2010 09h42 HE
|
Immune Network Ltd
VANCOUVER, British Columbia, Nov. 1, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), a company in the business of discovery and development of immune-based therapies, today announced...